Skip to main content
Premium Trial:

Request an Annual Quote

Invicro, Yale Partner to Advance Biomarker Detection Tech

NEW YORK — Invicro said on Monday that it has partnered with the Yale University School of Medicine to refine an imaging-based tissue biomarker detection technology for clinical pathology applications.

Under the deal, Invicro — a Boston-based subsidiary of Konica Minolta — will work with Yale pathologist David Rimm to advance Quanticell, a technology that uses photostable and bright phosphor-integrated dots for quantitative, amplification-free detection of proteins at cellular and subcellular levels.

According to Invicro, Rimm and his research team will evaluate different assay conditions to assess Quanticell's performance for quantifying HER-2 expression across a wider dynamic range than chromogenic-based immunohistochemistry.

Additional terms of the partnership were not disclosed.

"With his unmatched knowledge and experience in anatomical pathology, product commercialization, and late-stage clinical trials … Rimm is a leading pioneer in the quantitative pathology space," Ken Bloom, chief medical officer for advanced pathology solutions at Invicro, said in a statement. "I am highly confident that his efforts will support the advancement of Quanticell for specific drug development initiatives."